PharmaCyte Biotech, Inc. PMCB
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -15.66% | -688.22% | 110.07% | 11.27% | -171.15% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 9.77% | 369.86% | -123.98% | -13.83% | 152.12% |
| Change in Net Operating Assets | 83.24% | -5,101.44% | -116.04% | 113.58% | -175.91% |
| Cash from Operations | 43.93% | -77.00% | 19.67% | 50.88% | -91.66% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -100.00% | 266.67% | -- | -- |
| Cash from Investing | -- | -100.00% | 266.67% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -100.00% | -- | -- | -- |
| Repurchase of Common Stock | -- | 100.00% | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -100.00% | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.00% | 17.75% | -65.42% | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 50.88% | -131.22% | -91.24% | -- | -- |
| Foreign Exchange rate Adjustments | -185.71% | -73.08% | 750.00% | -500.00% | -83.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 44.61% | -132.81% | 113.65% | 211.73% | -64.61% |